Zealand Pharma A/S (OTCMKTS:ZLDPF) Shares Gap Down – What’s Next?

Zealand Pharma A/S (OTCMKTS:ZLDPF) gapped down before the market opened on Friday . The stock had previously closed at $60.00, but opened at $57.23. Zealand Pharma A/S shares last traded at $57.23, with a volume of 100 shares changing hands.

Wall Street Analysts Forecast Growth

Separately, William Blair raised Zealand Pharma A/S from a “hold” rating to a “strong-buy” rating in a research note on Friday, March 7th.

Zealand Pharma A/S Trading Down 1.4%

The business has a 50 day simple moving average of $66.33 and a 200-day simple moving average of $83.93. The company has a debt-to-equity ratio of 0.03, a quick ratio of 25.07 and a current ratio of 25.10. The stock has a market capitalization of $4.20 billion, a P/E ratio of -23.75 and a beta of 0.74.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.67) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.77) by $0.10. The firm had revenue of $1.14 million during the quarter, compared to analyst estimates of $248.61 million. Zealand Pharma A/S had a negative return on equity of 13.40% and a negative net margin of 2,127.09%. On average, analysts predict that Zealand Pharma A/S will post -2.19 EPS for the current year.

About Zealand Pharma A/S

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.